• The SMA NBS Alliance’s objective is for 100% of babies born in Europe to be screened for SMA by 2025.
• SMA Europe estimates that 25% of newborn babies in the EU were screened for SMA at the end of 2021.
• By the end of 2022, SMA Europe estimates 45% of newborns born in Europe will be screened for SMA. 40% considering the European continent including Russia and Turkey.

We are proud to announce that SMA Europe has officially joined the Screen4Rare platform as a Partner!

We at SMA Europe and on behalf of the entire SMA NBS Alliance are extremely grateful to receive the Black Pearl 2022 Company Award for Patient Engagement. We would like to thank EURORDIS-Rare Diseases Europe and all its nearly 1000 rare disease patient group members for this recognition.

There is no more time to waste for babies born with SMA! The European Alliance for SMA Newborn Screening demands Newborn screening programs for SMA in all countries no later than 2025! Learn from a diverse set of people on the importance of SMA newborn screening, let’s work together to make it a reality. We have the tools to detect and treat early, we need to use them to save individuals and families a lifelong disability.